Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
218.85 MXN
19.72 B MXN
159.95 B MXN
144.68 M
About Biogen Inc.
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Founded
1978
FIGI
BBG00JX0Q3Q8
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where BIIB is featured.
Frequently Asked Questions
The current price of BIIB is 3,625.00 MXN — it has increased by 2.69% in the past 24 hours. Watch BIOGEN INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange BIOGEN INC stocks are traded under the ticker BIIB.
We've gathered analysts' opinions on BIOGEN INC future price: according to them, BIIB price has a max estimate of 6,879.90 MXN and a min estimate of 3,621.00 MXN. Watch BIIB chart and read a more detailed BIOGEN INC stock forecast: see what analysts think of BIOGEN INC and suggest that you do with its stocks.
BIIB stock is 2.65% volatile and has beta coefficient of 0.76. Track BIOGEN INC stock price on the chart and check out the list of the most volatile stocks — is BIOGEN INC there?
Today BIOGEN INC has the market capitalization of 470.20 B, it has increased by 2.09% over the last week.
Yes, you can track BIOGEN INC financials in yearly and quarterly reports right on TradingView.
BIOGEN INC is going to release the next earnings report on Jan 30, 2025. Keep track of upcoming events with our Earnings Calendar.
BIIB earnings for the last quarter are 80.39 MXN per share, whereas the estimation was 74.33 MXN resulting in a 8.15% surprise. The estimated earnings for the next quarter are 69.89 MXN per share. See more details about BIOGEN INC earnings.
BIOGEN INC revenue for the last quarter amounts to 48.59 B MXN, despite the estimated figure of 47.97 B MXN. In the next quarter, revenue is expected to reach 49.36 B MXN.
BIIB net income for the last quarter is 7.65 B MXN, while the quarter before that showed 10.70 B MXN of net income which accounts for −28.49% change. Track more BIOGEN INC financial stats to get the full picture.
No, BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 7.57 K employees. See our rating of the largest employees — is BIOGEN INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN INC EBITDA is 54.15 B MXN, and current EBITDA margin is 22.58%. See more stats in BIOGEN INC financial statements.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN INC technincal analysis shows the neutral today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN INC stock shows the strong sell signal. See more of BIOGEN INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.